Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...
The recent setbacks also raise doubts about the heavy investment in AI and the feasibility of reaching an overarching goal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback